跳转至内容
Merck
CN

500586

JQ1 Enantiomers Set

别名:

JQ1 Enantiomers Set, (S)-tert-butyl 2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate, SGCBD01, BRD2 Inhibitor III, BRD3 Inhibitor II, BRD4 Inhibitor III, BRD6 Inhibitor I, BRDT Inhibitor I, BRD2 Inhibitor III, BRD3 Inhibitor II, BRD4 Inhibitor III, BRD6 Inhibitor I, BRDT Inhibitor I, (S)-tert-butyl 2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate, SGCBD01

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式(希尔记法):
C23H25ClN4O2S
分子量:
456.99
UNSPSC Code:
12352200
Assay:
≥96% (for both enantiomers, HPLC)
Form:
solid
Quality level:
Storage condition:
OK to freeze, protect from light
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助


assay

≥96% (for both enantiomers, HPLC)

Quality Level

form

solid

potency

50 nM Ki

manufacturer/tradename

Calbiochem®

storage condition

OK to freeze, protect from light

color

yellow-white

solubility

DMSO: 50 mg/mL (Each compound is soluble)

shipped in

ambient

storage temp.

−20°C

General description

A cell-permeable I-BET (Cat. No. 401010) class of thienodiazepine derivative whose (S)-(+), but not (R)-(-), enantiomer is shown to target both bromodomains (BD1 & BD2) of BET (bromodomain and extra terminal) family members BRD2 (KD = 128.4 nM for human BD1; ΔTmobs = 6.47 and 7.97 °C, respectively, for human BD1 and BD2), BRD3 (KD = 59.5 and 82.0 nM, respectively, for human BD1 and BD2), BRD4 (KD = 49.0 and 90.1 nM, respectively, for human BD1 and BD2), and BRD6/BRDT (KD = 190.1, 44.1, 77.5, and 59.2 nM, respectively, for human BD1, human BD2, murine BD1, and murine BD2) in a Kac- (ε-N-acetylated lysine) competitive manner, exhibiting little affinity toward 23 other BD-containing proteins, including the single BD-containing BRD1 and BRD9, and little or no activity against a panel of more than 50 receptors, ion channels, and transporters. Effectively inhibits the oncogenic BRD4-NUT (Nuclear protein in testis) fusion protein-dependent NMC (NUT midline carcinoma) and c-Myc oncoprotein-dependent MM (multiple myeloma) proliferation both in cultures (IC50<1 M) in vitro and in mice (50 mg/kg/day i.p.) in vivo. Also reported to cross the blood-testis boundary in male mice and effectively reduce testis mass, sperm count and motility (50 mg/kg; b.i.d. i.p.) in a reversible manner by targeting BRDT-mediated spermatogenesis without interfering hormone levels.

Biochem/physiol Actions

Cell permeable: yes
Primary Target
BRD4
Reversible: yes

Packaging

Packaged under inert gas

Physical form

Set contains 5 mg each of (S)-(+)-JQ1 enantiomer (540696-5MG) and (R)-(-) JQ1 enantiomer (500585-5MG)

Preparation Note

Following reconstitution, aliquot and freeze 9-20°C). Stock solutions are stable for up to 3 months at -20°C.

Other Notes

Matzuk, M. M., et al. 2012. Cell.150, 673.
Delmore, J. E., et al. 2011 Cell.146, 904.

Filippakopoulos, P., et al. 2010. Nature.468, 1067.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Toxicity: Standard Handling (A)


存储类别

11 - Combustible Solids

法规信息

新产品

此项目有



分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库



全球贸易项目编号

货号GTIN
500586-1SET04055977199352